Five Prime Therapeutics (FPRX) Posts Quarterly Earnings Results, Misses Estimates By $0.22 EPS

Share on StockTwits

Five Prime Therapeutics (NASDAQ:FPRX) released its quarterly earnings results on Tuesday. The biotechnology company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22), Fidelity Earnings reports. The company had revenue of $5.77 million during the quarter, compared to the consensus estimate of $7.45 million. Five Prime Therapeutics had a negative net margin of 206.02% and a negative return on equity of 40.61%.

NASDAQ:FPRX traded down $0.98 during trading hours on Wednesday, hitting $11.13. The company had a trading volume of 979,788 shares, compared to its average volume of 423,288. The stock has a market cap of $456.48 million, a P/E ratio of -2.07 and a beta of 3.23. Five Prime Therapeutics has a 52 week low of $10.35 and a 52 week high of $33.10.

FPRX has been the topic of several recent analyst reports. BidaskClub cut shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 26th. ValuEngine cut shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 28th. Wells Fargo & Co cut their price target on shares of Five Prime Therapeutics from $58.00 to $35.00 and set an “outperform” rating on the stock in a report on Thursday, August 9th. Wedbush lifted their price target on shares of Five Prime Therapeutics from $17.00 to $19.00 and gave the company a “hold” rating in a report on Friday, August 10th. Finally, Citigroup cut their price target on shares of Five Prime Therapeutics from $60.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 20th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $29.67.

ILLEGAL ACTIVITY NOTICE: This story was posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2018/11/07/five-prime-therapeutics-fprx-posts-quarterly-earnings-results-misses-estimates-by-0-22-eps.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

See Also: Diversification Important in Investing

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply